Compare Digital Realty Trust, Inc. (DLR) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Digital Realty Trust, Inc. vs Novo Nordisk A/S — how do they compare? Digital Realty Trust, Inc. trades at $176.79 (market cap $65.32B), while Novo Nordisk A/S trades at $38.51 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 2.5× Digital Realty Trust, Inc.'s market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Digital Realty Trust, Inc. for 94 Days and Novo Nordisk A/S for 116 Days on average.
| DLR | NVO | |
|---|---|---|
Market Cap | $65.32B | $165.31B |
Volume | 2,563,950 | 11,432,838 |
Sector | Real Estate | Health |
52-Week High | $203.91 | $63.98 |
52-Week Low | $147.93 | $35.29 |
Typical Hold Time | 94 Days | 116 Days |
Enterprise Value | $84.03B | $179.56B |
Dividend Yield | 2.77% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Digital Realty Trust (DLR) trades at $180.47, down 2.26% today, with a bearish technical signal despite strong analyst support. The data center REIT shows robust revenue growth to $6.11B in 2025 and expanding AI infrastructure partnerships, though valuation metrics remain elevated with a P/E of 85.89. Recent earnings show mixed results with Q2 2026 beating expectations by 150%.
DLR presents a compelling AI infrastructure play with strong growth prospects but faces valuation concerns and execution risks. The consensus price target of $222.35 suggests 23% upside potential, supported by 69% analyst buy ratings. Key risks include high leverage and competitive pressures in the rapidly expanding data center market.
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with a bullish technical signal supported by oscillators like RSI at 20.06 (buy signal). The company shows strong fundamentals with a P/E of 9.66, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights pipeline developments, including a Wegovy pill study showing continued weight loss and a $4 billion licensing deal, though an FDA delay for a hemophilia drug poses a near-term headwind.
The outlook remains positive with a consensus price target of $44.67, implying 17% upside, driven by robust profitability and growth in GLP-1 therapies. Risks include competitive pressure from Eli Lilly, regulatory delays, and reliance on obesity/diabetes drugs. Analyst sentiment is bullish (59% buy ratings), but investors should monitor execution amid high expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Digital Realty Trust, Inc.
Digital Realty owns and operates nearly 300 data centers worldwide. It has more than 35 million rentable square feet across five continents. Digital's offerings range from retail co-location, where an enterprise may rent a single cabinet and rely on Digital to provide all the accommodations, to cold shells, where hyperscale cloud service providers can simply rent much, or all, of a barren, power-connected building. In recent years, Digital Realty has de-emphasized cold shells and now primarily provides higher-level service to tenants, which outsource their related IT needs to Digital. Digital Realty has also moved more into the co-location business, increasingly serving enterprises and facilitating network connections. Digital Realty operates as a real estate investment trust.
Read more on DLR →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
